Biopharma Wake-up Call: Defending NIH, NSF & the foundation of U.S. science. There is an assault on U.S. science and silence is not an option, argue Luke Evnin, Peter Rubin and Peter Kolchinsky in a BioCentury Op-Edhttps://www.biocentury.com/article/654982

In BioCentury's 2nd story in our multipart look at Asia's NewCo Model, we focus on the VC angle. Investors with deep China roots like LAV & Orbimed have helped lead the surge, inspiring Western VCs to jump in. 50+ investors have invested in 13 NewCos www.biocentury.com/article/654907

Asia's "NewCo Model" kicked off in '21 with the launch of Arrivent and has hit its stride with 9 "NewCo" biotechs -- Asian assets with Western VC $ -- launching since July. 6 of 13 NewCos BioCentury ID'd are in I&I. Analysis by @fishburnsimone.bsky.social here: www.biocentury.com/article/654859

London’s icy wind with bouts of rain this week was perhaps more pathetic fallacy than anyone needed during the Jefferies London Healthcare conference and London Life Sciences Week, writes BioCentury Ed in Chief @fishburnsimone.bsky.social Here's her take on the mood in biotech in wake of Trump's win

RFK Jr. would be a disaster as HHS secretary, writes my BioCentury colleague Steve Usdin. For my part, I fear the approval of innovative drugs will slow to a crawl as FDA staffers leave the agency in droves and millions of children will go without vaccinations. I hope I am wrong.

And this just in...

Biopharma likely to persuade Congress to modify IRA’s Medicare drug price negotiation program & benefit from new FTC boss, says my BioCentury colleague Steve Usdin, but at cost of erosion in confidence in government & antagonism twd expertise, esp scientific. No Senate-confirmed position for RFK Jr.